Paul C. McGovern, MD

Senior Vice President, Medical Sciences
Venatorx Pharmaceuticals
Malvern, PA, United States

Paul McGovern, M.D. is the Senior V.P. Medical Sciences at Venatorx Pharmaceuticals. Prior to joining Venatorx Pharmaceuticals, Dr. McGovern has spent 16 years in anti-infective pharmaceutical development at Wyeth Pharmaceuticals / Pfizer, Actelion Clinical Research, Paratek Pharmaceuticals, and Venatorx Pharmaceuticals. Dr. McGovern has a B.S. from the University of Notre Dame and a M.D. from Northwestern University. He completed an Internal Medicine Residency and Infectious Diseases Fellowship at the University of Pennsylvania. Following the completion of his medical training, Dr. McGovern was a faculty member at the University of Pennsylvania prior to joining Wyeth Pharmaceuticals in 2006.

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 18 - New Antimicrobials and ID Diagnostics in the Pipeline - Bacterial

  Thursday, October 20, 2022
  8:00 AM – 9:00 AM US ET

• 48 - Cefepime-Taniborbactam, Venatorx Pharmaceuticals, Inc.

  Thursday, October 20, 2022
  8:10 AM – 8:20 AM US ET

• 731 - CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)

  Thursday, October 20, 2022
  2:00 PM – 2:15 PM US ET